Pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine
| العنوان: | Pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine |
|---|---|
| المؤلفون: | Lane B. Donaldson, Yuan F. Liu, Habib G. Rizk, D Macias, James R. Dornhoffer |
| المصدر: | The Journal of Laryngology & Otology. 134:586-591 |
| بيانات النشر: | Cambridge University Press (CUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Botulinum Toxins, Migraine Disorders, Botulinum toxin injection, Nortriptyline, Dizziness, Injections, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Oscillopsia, Pharmacotherapy, Refractory, Risk Factors, Topiramate, Internal medicine, medicine, Humans, Treatment Failure, Stage (cooking), 030223 otorhinolaryngology, Aged, Retrospective Studies, Aged, 80 and over, Vestibular system, business.industry, Retrospective cohort study, General Medicine, Middle Aged, Propranolol, Botulinum toxin, Verapamil, Otorhinolaryngology, Female, medicine.symptom, business, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | ObjectiveGiven the lack of evidence on patients with medically refractory vestibular migraine, this study aimed to identify factors associated with pharmacotherapy failure and progression to botulinum toxin injection in vestibular migraine.MethodsA retrospective cohort study was conducted on definite vestibular migraine patients from September 2015 to July 2019 who completed the Dizziness Handicap Inventory at least six weeks apart..ResultsThe study comprised 47 patients (mean age = 50.2 ± 15.8 years), with a mean follow-up time of 6.0 ± 6.0 months. The mean pre-treatment Dizziness Handicap Inventory score was 57.5 ± 23.5, with a mean reduction of 17.3 ± 25.2 (p < 0.001) at last follow up. Oscillopsia (r = 0.458, p = 0.007), failure of first medication (r = 0.518, p = 0.001) and pre-treatment Dizziness Handicap Inventory question 15 (an emotional domain question) score (r = 0.364, p = 0.019) were the only variables significantly correlated with progression to botulinum toxin injection.ConclusionMotion hypersensitivity, failure of first medication, and fear of social stigmatisation suggest a decreased treatment response. These symptoms may require more aggressive treatment at an earlier stage. |
| تدمد: | 1748-5460 0022-2151 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::841d41714b2dcaf11f173c5104df5aa3Test https://doi.org/10.1017/s002221512000095xTest |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....841d41714b2dcaf11f173c5104df5aa3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17485460 00222151 |
|---|